FOSL1 triggers the activation of the IL-6/JAK/Stat3 signaling pathway, resulting in a malignant switch in breast tumor cells that leads to increased release of pro-angiogenic factors such as MMP-9, VEGF, and TGF-β from the tumor cells. This evidence concerns the gene FOSL1 and neoplasm.